ATE454154T1 - Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung - Google Patents

Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung

Info

Publication number: ATE454154T1
Authority: AT; Austria
Prior art keywords: duration; activity; alkyl; topical; increase
Prior art date: 2003-06-19

Application number

AT04755493T

Other languages

English (en)

Inventor

Nicholas S Bodor

Original Assignee

Nicholas S Bodor

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-19

Filing date

2004-06-17

Publication date

2010-01-15

2004-06-17 Application filed by Nicholas S Bodor filed Critical Nicholas S Bodor

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE454154T1 publication Critical patent/ATE454154T1/de

Links

230000000694 effects Effects 0.000 title abstract 3
230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
150000003431 steroids Chemical class 0.000 title abstract 2
230000000699 topical effect Effects 0.000 title 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
230000002708 enhancing effect Effects 0.000 abstract 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 abstract 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
125000001188 haloalkyl group Chemical group 0.000 abstract 1
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract 1
229960003744 loteprednol etabonate Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)

AT04755493T 2003-06-19 2004-06-17 Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung ATE454154T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47949603P	2003-06-19	2003-06-19
PCT/US2004/019367 WO2005000317A1 (en)	2003-06-19	2004-06-17	Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application

Publications (1)

Publication Number	Publication Date
ATE454154T1 true ATE454154T1 (de)	2010-01-15

Family

ID=33551891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04755493T ATE454154T1 (de)	2003-06-19	2004-06-17	Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung

Country Status (11)

Country	Link
US (2)	US7560448B2 (de)
EP (1)	EP1653974B1 (de)
JP (1)	JP4893305B2 (de)
KR (1)	KR20060032596A (de)
CN (1)	CN1838960A (de)
AT (1)	ATE454154T1 (de)
CA (1)	CA2558944C (de)
DE (1)	DE602004025002D1 (de)
ES (1)	ES2339351T3 (de)
MX (1)	MXPA05013898A (de)
WO (1)	WO2005000317A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
ATE529399T1 (de) *	2005-11-10	2011-11-15	Nicholas S Bodor	Sanfte anticholinerge ester
WO2007058935A2 (en) *	2005-11-14	2007-05-24	Bausch & Lomb Incorporated	Ophthalmic composition for dry eye therapy
GB0523251D0 (en) *	2005-11-15	2005-12-21	Glaxo Group Ltd	Novel compounds
US7767217B2 (en) *	2006-03-14	2010-08-03	Foresight Biotherapeutics	Ophthalmic compositions comprising povidone-iodine
US7691811B2 (en) *	2006-05-25	2010-04-06	Bodor Nicholas S	Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) *	2006-05-25	2010-03-30	Bodor Nicholas S	Transporter enhanced corticosteroid activity
MX2009009213A (es) *	2007-03-01	2010-03-15	Univ America Catholic	Bacteriofago t4 unido a un substrato.
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en)	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (de)	2008-07-01	2019-06-12	Curemark, Llc	Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en)	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
CA2747611C (en)	2009-01-06	2019-09-17	Curemark Llc	Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010080835A1 (en) *	2009-01-06	2010-07-15	Curemark Llc	Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en)	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
JP5976100B2 (ja)	2011-04-21	2016-08-23	キュアマークリミテッドライアビリティカンパニー	神経精神障害の処置のための化合物
US8835410B2 (en) *	2011-05-10	2014-09-16	Bodor Laboratories, Inc.	Treatment of eyelid dermatitis
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
US12226464B2 (en)	2017-04-10	2025-02-18	Curemark, Llc	Compositions for treating addiction
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022225999A1 (en) *	2021-04-19	2022-10-27	Bodor Laboratories, Inc.	Lung-targeted corticosteroid treatment in viral respiratory disease, covid-19 and ards (acute respiratory distress syndrome)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1384372A (en)	1971-01-20	1975-02-19	Glaxo Lab Ltd	Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) *	1972-01-20	1974-08-06	Glaxo Lab Ltd	Androstane-17beta-carboxylic acids and processes for the preparation thereof
CH628355A5 (de) *	1976-02-24	1982-02-26	Ciba Geigy Ag	Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4996335A (en) *	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
ZA814440B (en) *	1980-07-10	1982-10-27	Otsuka Pharma Co Ltd	Soft steroids having anti-inflammatory activity
US4710495A (en) *	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
US4496335A (en) *	1982-12-13	1985-01-29	Dayco Corporation	Pulley construction and method of making the same
US5981517A (en) *	1996-05-09	1999-11-09	Soft Drugs, Inc.	Androstene derivatives
TW503113B (en) *	1997-01-16	2002-09-21	Senju Pharma Co	Aqueous suspension for nasal administration
KR100508227B1 (ko) *	1997-03-14	2006-03-23	센주 세이야꾸 가부시키가이샤	로테프레드놀에타보네이트수성현탁액
WO2001060413A2 (en)	2000-02-15	2001-08-23	Board Of Trustees Of The University Of Arkansas	Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases

2004
- 2004-06-17 WO PCT/US2004/019367 patent/WO2005000317A1/en not_active Ceased
- 2004-06-17 AT AT04755493T patent/ATE454154T1/de not_active IP Right Cessation
- 2004-06-17 CN CNA2004800231439A patent/CN1838960A/zh active Pending
- 2004-06-17 CA CA2558944A patent/CA2558944C/en not_active Expired - Lifetime
- 2004-06-17 DE DE602004025002T patent/DE602004025002D1/de not_active Expired - Lifetime
- 2004-06-17 EP EP04755493A patent/EP1653974B1/de not_active Expired - Lifetime
- 2004-06-17 ES ES04755493T patent/ES2339351T3/es not_active Expired - Lifetime
- 2004-06-17 KR KR1020057024345A patent/KR20060032596A/ko not_active Ceased
- 2004-06-17 US US10/868,966 patent/US7560448B2/en active Active
- 2004-06-17 JP JP2006517352A patent/JP4893305B2/ja not_active Expired - Fee Related
- 2004-06-17 MX MXPA05013898A patent/MXPA05013898A/es active IP Right Grant
2009
- 2009-06-09 US US12/480,953 patent/US7923441B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20090239833A1 (en)	2009-09-24
JP4893305B2 (ja)	2012-03-07
US7560448B2 (en)	2009-07-14
US20050026892A1 (en)	2005-02-03
KR20060032596A (ko)	2006-04-17
EP1653974A1 (de)	2006-05-10
MXPA05013898A (es)	2006-05-25
JP2007520437A (ja)	2007-07-26
CA2558944A1 (en)	2005-01-06
CN1838960A (zh)	2006-09-27
WO2005000317A1 (en)	2005-01-06
DE602004025002D1 (de)	2010-02-25
HK1089690A1 (en)	2006-12-08
ES2339351T3 (es)	2010-05-19
EP1653974B1 (de)	2010-01-06
US7923441B2 (en)	2011-04-12
CA2558944C (en)	2012-05-29

Legal Events

Date	Code	Title	Description
2010-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE454154T1 (de)	2010-01-15	Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung
MX2009004616A (es)	2009-05-22	Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
TW200603813A (en)	2006-02-01	Cyclic progestin regimens and kits
TWD136875S1 (zh)	2010-09-11	錶盤
AR034407A1 (es)	2004-02-25	Peptidos lineales selectivos con actividad agonista de receptor de melanocortina-4 (mc4-r)
CR8796A (es)	2007-08-28	Compuestos amido y su uso como farmacos
PA8572201A1 (es)	2004-03-10	Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona
MY153910A (en)	2015-04-15	BICYCLIC y-AMINO ACID DERIVATIVE
HRP20070169A2 (en)	2007-09-30	Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
NZ524104A (en)	2004-12-24	Exemestane as chemopreventing agent
ATE540667T1 (de)	2012-01-15	Verbindungen mit kühlender wirkung
ATE445389T1 (de)	2009-10-15	Liposomale glucocorticoide
ATE369138T1 (de)	2007-08-15	Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
DE602004026558D1 (de)	2010-05-27	Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren
TW200626161A (en)	2006-08-01	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TNSN06138A1 (fr)	2007-11-15	Inhibitors of the mutant form of kit
ATE492282T1 (de)	2011-01-15	Zusammensetzung aus steroiden mit transporterweiterter corticosteroid-aktivität
CO6150165A2 (es)	2010-04-20	Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia
BR0308660A (pt)	2005-01-25	C-17 espirolactonização e 6,7 oxidação de esteróides
DE602006012115D1 (de)	2010-03-25	Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
ATE415395T1 (de)	2008-12-15	Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
NZ528138A (en)	2006-03-31	Stud assembly with plate between studs having longitudinal U or V shape for sound attenuation
NZ588470A (en)	2012-12-21	Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases
BR112022004441A2 (pt)	2022-06-07	Agente para melhorar distúrbio de micção
JP1730208S (ja)	2022-11-18	電動車